American Express Co vs Twist Bioscience Corp — how do they compare? American Express Co trades at $341.25 (market cap $230.15B), while Twist Bioscience Corp trades at $123.98 (market cap $7.72B). The key difference: American Express Co is far larger — about 29.8× Twist Bioscience Corp's market cap, and American Express Co pays a 1.11% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| AXP | TWST | |
|---|---|---|
Market Cap | $230.15B | $7.72B |
Sector | Financials | Health |
52-Week High | $384.82 | $124.88 |
52-Week Low | $292.27 | $24.16 |
Dividend Yield | 1.11% | — |
Enterprise Value | — | $7.65B |
Signals from Pluang's Aura AI — not financial advice
American Express (AXP) trades at $338.86, down 0.6% with bearish technical signals despite strong fundamentals. The company reported solid Q2 2026 earnings beat ($4.53 vs $4.41 expected) and maintains robust profitability with 15.07% net margin and 33.97% ROE. Recent news highlights Amex Ventures' AI investments and premium card member experiences, while Berkshire Hathaway's 20% ownership underscores long-term confidence in the business model.
AXP presents a mixed outlook with strong fundamental performance offset by technical weakness. The stock offers 9% upside to consensus price target of $369.42, supported by revenue growth and premium positioning, but faces headwinds from bearish technical indicators and competitive pressure in digital payments. Risk-reward appears balanced near current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →